You are here

FDA Reports Recent Case of Brain Infection With Gilenya

Patients with weak immunity most at risk (August 29)
This is the first case of progressive multifocal leukoencephalopathy (PML) reported following the administration of fingolimod to a patient who had not previously received natalizumab (Tysabri, Biogen Idec), a medication for MS that is associated with a higher risk of PML. Fingolimod is used to treat relapsing forms of MS, which affects the brain and spinal cord.

PML is caused by the John Cunningham (JC) virus, which damages myelin, the fatty covering of the brain. PML usually results in death or severe disability and mostly affects those with weakened immune systems.

Patients should not discontinue fingolimod therapy without first consulting their health care professional. Novartis stated that the firm does not believe fingolimod was responsible for PML in this case. The patient was taking other drugs besides fingolimod, Novartis and the FDA explained.

Source: FDA

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs